Sentence examples for a more powerful study from inspiring English sources

Although not significant, both augmentation index and ISI index was more favourable in the high MBL group, also suggesting a better arterial function in this group, and a more powerful study including more patients might confirm this association.

The effect sizes seen in ICAS and NCICAS were somewhat smaller but showed greater statistical significance because the studies included more children and had a more powerful study design (i.e., randomized, controlled trial) than did HEAL.

I showed that the combination of more powerful study designs and more accurate exposure assessment together with a better understanding of mechanisms of disease and the use, in the case of dioxins, of biomarkers of exposure, led to the strengthening of the epidemiological evidence.

Owing to development of more powerful study designs, the availability of dense marker maps, progress in high-throughput genotyping and a better basic understanding of the roles of genes in the immune system, this trend is likely to continue.

In addition to helping understand disease by providing more powerful study models, "what this technology would allow you to do is reprogram a skin cell, for example, from a Parkinson's patient... into a pluripotent cell and then in a petri dish redirect that cell into... a neuron" to treat that patient.

However, we did observe a non-significant trend for the rate of de novo CNVs to be higher in BD than in controls, suggesting that larger and more powerful studies might reveal a significant excess.

In any case, a larger sample is certainly required for a more powerful replication study.

Over-enriching a population by selecting only subjects who are nearly certain to progress to AD at a rapid rate may result in what looks like a more powerful clinical study, but the results are not likely to be generalizable to a broader population and we may be excluding the subjects whose progression is slow enough that we have time to intervene.

Looking ahead, we would propose larger and more powerful studies on the use of ERCC1 as a cisplatin sensitivity biomarker as it is currently the most promising lead.

Thus, further investigation is necessary to elucidate these dynamics, both in terms of study design and physiology, perhaps using more precise tools to assess diet or in more powerful studies of different design (e.g. intervention studies adequately powered to test gene treatment interactions).

Consequently, more powerful studies are needed to reach firmer conclusions on this matter.